Background
Immunoglobulin G4 (IgG4)-related disease is a fibroinflammatory disease characterized by fibrous tissue and lymphoplasmocytic infiltration [
1]. IgG4-related hypophysitis is a novel classification of primary hypophysitis. It may be associated with other organ involvements or confined in the pituitary [
2]. The presence of IgG4-related systemic diseases, the elevation of serum IgG4 level, and the dramatic response to steroid therapy are important clinical clues to establish the diagnosis of IgG4-related hypophysitis [
2,
3]. However, there is an extensive overlap between the clinical spectrum of lymphocytic hypophysitis and IgG4-related hypophysitis. To differentiate these conditions based on clinical manifestations can be problematic. We thereby present other clinical clues that may support the diagnosis of IgG4-related hypophysitis.
Discussion
We report a case of biopsy-proven IgG4-related hypophysitis which clinically mimicked a recurrent lymphocytic hypophysitis. Our patient presented with focal seizure and multiple anterior pituitary hormone deficiency. He had typical imaging changes for hypophysitis with vividly enhanced sellar-suprasellar mass and stalk enlargement. The pituitary histopathology showed infiltration of lymphocytes, plasma cells and fibrosis, reflecting chronic inflammatory lesions. From the combination of clinical manifestation, imaging, and initial histopathology; the first impression was lymphocytic hypophysitis. The diagnosis of IgG-4 related hypophysitis was obtained one year later after pathological review.
IgG4-related hypophysitis is a new entity of primary hypophysitis. Like other organ involvements in IgG4-related disease, histopathology is the cornerstone for diagnosis. It is characterized by the infiltration of IgG4-containing plasma cells, lymphocytes, and storiform fibrosis. In 2011, Leporati et al. proposed three criteria for diagnosis of IgG4-related hypophysitis [
2]. Fulfillment of any of these three criteria is sufficient for the diagnosis to be made. The first criterion requires a histopathological biopsied of pituitary that shows mononuclear cells infiltration with more than 10 IgG4-positive cells per high power field. The second criterion requires a pituitary MRI that reveals typical lesions for hypophysitis and a tissue biopsy from another organ showing IgG4 lesion. The third criterion is composed of three components including typical hypophysitis lesions from MRI imaging, an increase in serum IgG4 levels and prompt clinical response to steroids. Clearly the uses of second criterion are rather limited in patients with isolated hypophysitis IgG4-related disease such as in this patient.
To diagnose IgG4-related hypophysitis without evidence of other organ involvement is challenging. Routine H&E staining in histopathology is not sufficient to differentiate IgG4-related hypophysitis from other causes of chronic hypophysitis. The immunohistochemistry stain for IgG4 in the pituitary tissue biopsy is a useful tool to help establish a diagnosis. However, certain limitations exist in this technique. Firstly sampling error from inadequate specimens can result in a negative report. Secondly, clusters of IgG4-positive cells can also be found in other causes of hypophysitis [
4,
5]. Lastly, there is also a report in the paucity of IgG4-positive plasma cells from pituitary tissue, despite having IgG4-positive plasma cell in other organs [
6]. Multiple other pitfalls also exist in using clinical criteria to differentiate IgG4-related hypophysitis from lymphocytic hypophysitis. For example, serum IgG4 level may be normalized after initial steroid administration [
3,
4]. This is particularly common in patients with hypocortisolism-associated hypophysitis. The sellar mass and/or thickened pituitary stalk in pituitary MRI are also commonly found in other causes of hypophysitis. The dramatic response to steroid therapy, including clinical improvement, regression of sellar mass and resolution of associated inflammation, can also be witnessed in lymphocytic hypophysitis. Thus, a high index of suspicious is required to establish a diagnosis of IgG4-related hypophysitis.
Patient backgrounds and clinical courses can serve as useful tools in differentiating isolated-IgG4 related hypophysitis from Lymphocytic hypophysitis. Lymphocytic hypophysitis is typically found in female whereas IgG4-related hypophysitis is more common in elderly male with Asian ethnicity [
3]. The recurrence or worsening of clinical symptoms while receiving steroid therapy is unusual in patients with lymphocytic hypophysitis. Their clinical symptoms are rather stable with most experiencing gradual improvement after physiologic or supraphysiologic dosage of steroid therapy [
7,
8]. In contrast, patients with IgG4-related hypophysitis can experience relapse of symptoms when receiving steroid therapy. To the best of our knowledge, 38 cases (include this case) of IgG-4 related hypophysitis, have been reported in English literatures and were all compatible with Leporati’s criteria [
2,
6,
9‐
34]. In these reports, 24 cases were male, 28 cases were Asian and the median age of onset was 67 years. Up to six cases revealed enlarging masses on imaging or developed new symptom relating to the sellar mass during steroid therapy [
2,
6,
11,
18,
27]. These symptoms included visual disturbance, headache, diabetes insipidus or progression of hypopituitarism. Steroid dosage at the point of relapse varied from 30 mg of prednisolone per day to hydrocortisone replacement therapy. All patients eventually required up-titration of steroid or additional immunosuppressive therapy to control their relapsing clinical symptoms. Five out of six cases were also initially diagnosed with lymphocytic hypophysitis where three of these cases also had pituitary biopsy and histopathology study prior to their diagnosis (Table
2).
Table 2
Clinical characteristic of relapsing of Immunoglobulin G4 (IgG4)-related hypophysitis during steroid therapy
| M 75 y, Japanese | Autoimmune pancreatitis, uveitis, organizing pneumonia, panhypopituitarism with mass (Lymphocytic hypophysitis)b
| Pred 50 mg/day for 1 week then taper to 10 mg/day within 7 months | Recurrent pituitary mass and organizing pneumonia | Pred 50 mg/day then 20 mg/day, contracted pituitary mass |
| M 68 y, Japanese | Diabetes insipidus and gradual loss of anterior pituitary function with mass (Lymphocitic hypophysitis)b, retroperitoneal fibrosis | Hydrocortisone replacement for 4 years | Headache, pituitary swelling | Pred 30 mg/day for 2 weeks then 10 mg/day, decrease pituitary swelling |
| M 75 y, Caucasian | Panhypopituitarism with mass, sphenoid mass | Pred 40 mg/day taper to 10 mg/day over 4 weeks | Recurrent headache | Pred 15 mg/day, then taper/reescalation and suspend until 1.3 years, improved headache but hypopituitarism |
| M 40 y, Vietnamese | Lacrimal gland mass, diabetes insipidus, panhypopituitarism with mass (Lymphocytic hypophysitis)a, enlarged infraorbital nerve | Pred 30 mg/day for 3 months | Enlarging pituitary mass with new optic nerve compression | Azathioprine 75 mg twice daily whilst weaning Pred for 10 months, recovery from adrenal insufficiency and growth hormone deficiency, ongoing bilaterally enlarged infraorbital nerves but normal pituitary size |
| M 70 y, Japanese | Hashimoto’s thyroiditis, pancreatic and retroperitoneal mass, salivary gland enlargement, pituitary mass, bitemporal hemianopsia (Lymphocytic hypophysitis)a
| Pred 40 mg/day for 2 weeks then taper to 5 mg/day | Reduction in pituitary lesion, improved vision but new DI and panhypopituitarism | Pred 30 mg/day then taper to 5 mg/day for 2 months, no further pituitary mass reduction and did not restore the pituitary function |
Hydrocortisone 100 mg on day of surgery + Pred 5 mg/day for 1 month |
Ngaosuwan, 2015 (the presented case) | M 43 y, Thai | Frontal lobe seizure, multiple pituitary hormone deficiency with pituitary mass (Lymphocytic hypophysitis)a
| Pred 15 mg/day for 6 weeks, 10 mg/day for 3 months, and 7.5 mg/day for 3 months | Bitemporal hemianopsia, Headache, Inflammation of optic chiasm | Pred 60 mg/day for 2 weeks, gradually decrease to 30 mg/day for 4 weeks, 20 mg/day for 4 weeks, and 10 mg/day for maintenance, complete recovery of vision, contracted pituitary mass, decreased optic chiasmatic swelling, but did not restore pituitary function |
This patient presented with frontal lobe seizure semiology that did not recur after steroid initiation. Frontal lobe lesion in MRI also completely regressed after low dose steroid administration. This clinical picture is unusual for cerebral infarctions, therefore statin and aspirin are futile for secondary prevention of stroke. Although, no parenchymal tissue was obtained, IgG4-related disease involvement was highly suspected. Biopsy-proven central nervous system involvement in IgG4-related disease was also reported [
35,
36]. Unlike our patient, the reported patients presented with tremor, dementia and weakness. Various reports also described cases of IgG4-related hypophysitis with parasellar inflammation, sinusitis, and pachymeningitis [
2,
15,
27,
29]. Thus, we speculated that the newly developed visual field defect in this patient, despite decreasing in size of sellar mass, could be attributed to associate pachymeningitis around sellar and optic chiasmatic area. Hence, the escalation of systemic steroid was sufficient to control the patient symptoms and surgical intervention was unnecessary.
Despite an absence of posterior bright spot in MRI, the patient had no sign and symptom of diabetes insipidus. The absence of posterior bright spot in MRI was reported in about 0 to 25 % of normal subjects [
37,
38]. However, our patient had anterior pituitary dysfunction with mass and enlarged stalk; hence we suspected that some degree neurohypophyseal inflammation existed without causing gross disturbance in vasopressin secretion. This inflammation only resulted in a partial depletion of vasopressin which was asymptomatic and normal range of urine osmolarity was preserved. Other case reports of IgG4-related hypophysitis also showed an absence of posterior bright spot in MRI imaging in patients without clinical diabetes insipidus [
11,
23]. Thus, closed monitoring for diabetes insipidus is warranted. One year after steroid escalation, there was an improvement in gonadal function and pituitary mass was controlled. Nevertheless, most of anterior pituitary hormones still depressed. Long term follow up is recommended for understanding the natural course of IgG4-related hypophysitis.
Conclusion
This is the first case report in patient with IgG4-related hypophysitis who initially presented with focal seizures and relapsing lymphocytic hypophysitis. Due to its rarity and the overlapping clinical picture, it is often difficult to differentiate IgG4-related hypophysitis from lymphocytic hypophysitis with initial clinical manifestations, imaging studies, and routine histopathology. This case report highlights the distinctive clinical course between the two diseases. A close clinical follow-up is, therefore, essential in patients with lymphocytic hypophysitis. A diagnosis of IgG4-related hypophysitis should be considered in patients with worsening clinical course during the steroids decrement or patients with concomitant pachymeningitis. These patients should undergo further evaluation including clinical assessment for other organ involvement, measuring serum IgG4 level and additional tissue immunostaining. Timely treatment with high dose steroid is advised to prevent permanent disability and unnecessary invasive surgical interventions.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KN cared the patient, prepared the manuscript, and arranged for the radiological imaging of the patient. TT participated in histopathological study. SS interpreted histopathological study and arranged for the pathological imaging of the patient. All authors read and approved the final manuscript.
Kanchana Ngaosuwan, MD.
Staff at Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Srinakharinwirot University, Ongkarak Nakhon Nayok, Thailand.
Therdkiat Trongwongsa, MD.
Staff at Department of Pathology, Faculty of Medicine, Srinakharinwirot University, Ongkarak Nakhon Nayok, Thailand.
Shanop Shuangshoti, MD.
Professor at Department of Pathology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.